Trial Profile
Evaluation of Effectiveness and Safety of Resolute Onyx in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arterial occlusive disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-Onyx
- 17 Dec 2023 Planned number of patients changed from 4000 to 4500.
- 17 Dec 2023 Planned End Date changed from 30 Sep 2027 to 31 Dec 2029.
- 17 Dec 2023 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2025.